Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era

Published:2016-12-22 Issue:3 Volume:13 Page:226-233
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Tamjid Babak¹²,Mckendrick Joseph¹,Schwarer Anthony¹²,Doig Rowan¹,James Philip¹,Hosking Patrick³,Hawkes Eliza A¹²⁴

Affiliation:

1. Oncology and Haematology Department, Box Hill Hospital; Melbourne Victoria Australia

2. Department of Medical Oncology & Clinical Haematology; Olivia Newton John Cancer Research Institute, Austin Hospital; Melbourne Victoria Australia

3. Pathology Department; Box Hill Hospital; Melbourne Victoria Australia

4. Monash University; Melbourne Victoria Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12611/fullpdf

Reference28 articles.

1. Statistics SC 2015

2. My treatment approach to patients with diffuse large B-cell lymphoma;Armitage;Mayo Clin Proc,2012

3. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting;Gisselbrecht;Br J Haematol,2008

4. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma;Corazzelli;Cancer Chemother Pharmacol,2009

5. Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy;El Gnaoui;Ann Oncol,2007

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of RAD51, XRCC1, XRCC2, and XRCC3 Polymorphisms with Risk of Breast Cancer;Genetic Testing and Molecular Biomarkers;2023-07-01

2. Antineoplastics;Reactions Weekly;2017-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3